Down 87% Over 5 Years… Now This Biotech Could End Insulin Shots Forever

Imagine being the CEO of a company down 87% over five years (I mean at that point, you’d probably be debating whether or not you should rob a bank). That’s where Sana Biotechnology was just yesterday… the poster child for biotech heartbreak. But today, they decided to pull a Lazarus. Shares are up an astronomical 199% so far today, all thanks to some “groundbreaking” (their words) Type 1 diabetes clinical trial results.

Sana announced results from an early-stage trial of its islet cell therapy, designed to help people with Type 1 diabetes produce their own insulin. Oh, and the science behind it is pretty cool. They’ve developed a tech called UP421 that uses engineered pancreatic beta cells. What really makes this unique is that these cells can be transplanted without needing immunosuppressive drugs…a historic invention in the world of cell therapy.

The trial, done in partnership with Sweden’s Uppsala University Hospital (because of course Sweden’s involved… they’re good at this stuff), showed some pretty amazing results. Four weeks post-transplant, the transplanted cells were not only surviving but thriving. Blood tests detected C-peptide, a marker for insulin production, and MRI scans confirmed the cells were still hanging out and doing their job. Oh, and no safety issues. For a company that’s been on the ropes, this is like winning the lottery. Per-Ola Carlsson, the lead researcher, called the results a beacon of hope: “Today’s data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative treatment for patients with Type 1 diabetes… is possible.” In other words: 200 million people worldwide who currently jab themselves with insulin daily might someday trade needles for something way cooler… like functioning beta cells.

As you know, biotech is all about potential, and Sana just showed theirs. Before this news, analysts had a $10 price target on the stock. Today’s rocketship to $5.66 makes that target seem a lot more achievable. The stock is now trading at levels we haven’t seen since August 2022. Remember August 2022? It feels like a lifetime ago, back when our investment accounts seemed like they’d never stop bleeding. That said, let’s not forget the company’s track record. Sana went public in 2021 at a $4 billion valuation and has since watched its market cap dwindle to under $400 million. Today’s jump is impressive, but it’s a long road back to those early days.

It’s important to keep some perspective here. This trial involved one patient. One. Sure, the results are promising, but there’s a long road between this and FDA approval. The biotech graveyard is filled with companies that soared on early data, only to crash when the hard questions came up.

Sana’s stock surge is a feel-good moment for the company and its investors. If these results hold up in larger trials, they could be onto something transformative for Type 1 diabetes treatment. But as exciting as today’s news is, it’s worth remembering that biotech is the most feast or famine industry in the world (probably).

PS: If you want to have full access to our Insider Trader Tool and see where executives and congress members are piling their millions, all you have to do is become a Stocks.News Premium member (it’s less than the cost of a HBO Max subscription). Go here and start piggybacking the insider’s trades, there’s a reason these folks are crushing the best hedge funds to ever exist by triple digits.

Stock.News does not have positions in companies mentioned